# US 2022/0009964 A1 · Blood-brain barrier permeable peptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0009964 A1
- Document ID: US20220009964A1
- Status: Published application
- Kind: A1
- Application number: 17/260,108
- Filed: 2019-07-16
- Published: 2022-01-13
- Earliest claimed: 2018-07-17
- Assignees: National University Corporation Kumamoto University
- Applicants: National University Corporation Kumamoto University
- Inventors: Shingo ITO; Sumio OHTSUKI; Shunsuke YAMAGUCHI
- Web page: https://patentgrep.com/patent/US20220009964A1

## CPC

- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- C07K 7/06: having 5 to 11 amino acids
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 49/00: Preparations for testing in vivo
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention has an object of providing a novel peptide that is permeable to the blood-brain barrier. The present invention provides a blood-brain barrier permeable peptide containing an amino acid sequence: SLSHSPQ (SEQ ID NO: 1) (where P may be substituted). The present invention also provides a carrier molecule for intracerebral delivery containing the peptide, a complex composed of the peptide and a target molecule that is allowed to permeate the blood-brain barrier, and a blood-brain barrier permeable composition containing the complex.

## Claims

### Claim 1

(canceled)

### Claim at position 2

2-24. (canceled)

### Claim 25

A peptide capable of permeating blood brain barrier comprising at least one of the following amino acid sequence:
(i) an amino acid sequence consisting of SLSHSPQ (SEQ ID NO: 1), or
(ii) an amino acid sequence shown in SEQ ID NO: 1, in which P is substituted with an amino acid selected from the group consisting of A, I, L, V, M, F, W, Y, S, T, N, Q, H and G.

### Claim 26 (depends on 25)

The peptide according to claim 25, comprising at least one unnatural amino acid.

### Claim 27 (depends on 25)

The peptide according to claim 25, wherein the peptide is a cyclic peptide.

### Claim 28 (depends on 25)

The peptide according to claim 25, wherein the peptide is a peptide selected from the group consisting of the following (a) to (g):
(a) a peptide consisting of an amino acid sequence: SLSHSPQ (SEQ ID NO: 1),
(b) a peptide having 1 to 5 amino acid(s) at the C-terminal and/or the N-terminal of the amino acid sequence of SLSHSPQ (SEQ ID NO: 1) respectively,
(c) a peptide consisting of an amino acid sequence: CSLSHSPQC (SEQ ID NO: 2) in which cysteine residues in the sequence are disulfide-bonded,
(d) a peptide having 1 to 10 amino acid(s) at the C-terminal and/or the N-terminal of the amino acid sequence of CSLSHSPQC (SEQ ID NO: 2) respectively, in which cysteine residues in the sequence are disulfide-bonded,
(e) a peptide represented by an amino acid sequence of the following formula (1):
wherein, AAa and AAd each independently represent 1 to 10 amino acid(s), and AAb and AAc each independently represent 1 to 5 amino acids,
(f) a peptide having 1 to 15 amino acid(s) at the C-terminal and N-terminal of the amino acid sequence of SLSHSPQ (SEQ ID NO: 1) respectively, in which amino acids located on each side of the sequence are crosslinked together, and
(g) the peptide as described in any one of (a) to (f) above, in which P in the amino acid sequence SLSHSPQ is substituted with an amino acid selected from the group consisting of A, I, L, V, M, F, W, Y, S, T, N, Q, H and G.

### Claim 29 (depends on 28)

The peptide according to claim 28, which comprises at least one unnatural amino acid.

### Claim 30

A carrier for intracerebral delivery comprising a peptide capable of permeating blood-brain barrier comprising at least one of the following amino acid sequence:
(i) an amino acid sequence sequence consisting of SLSHSPQ (SEQ ID NO: 1), or
(ii) an amino acid sequence shown in SEQ ID NO: 1, in which P is substituted with an amino acid selected from the group consisting of A, I, L, V, M, F, W, Y, S, T, N, Q, H and G.

### Claim 31 (depends on 30)

The carrier for intracerebral delivery according to claim 30, further comprising a carrier molecule for drug delivery selected from the group consisting of liposomes, nanocarriers, exosomes, phages, polyrotaxanes, cyclodextrins, microcapsules and micelles.

### Claim 32 (depends on 30)

The carrier for intracerebral delivery according to claim 30, further comprising a substance selected from the group consisting of transferrin, fibrinogen, and a peptide containing RGD sequence.

### Claim 33

A complex comprising:
a peptide capable of permeating blood brain barrier comprising at least one of the following amino acid sequence:
an amino acid sequence consisting of SLSHSPQ (SEQ ID NO: 1), or
an amino acid sequence shown in SEQ ID NO: 1, in which P is substituted with an amino acid selected from the group consisting of A, I, L, V, M, F, W, Y, S, T, N, Q, H and G; and
a molecule that permeates the blood-brain barrier with the peptide.

### Claim 34 (depends on 33)

The complex according to claim 33, further comprising a substance selected from the group consisting of transferrin, fibrinogen, and a peptide containing RGD sequence.

### Claim 35 (depends on 33)

The complex according to claim 33, wherein the molecule is a molecule that exhibits a pharmacological action in the brain or an intracerebral imaging molecule.

### Claim 36 (depends on 33)

The complex according to claim 33, wherein the molecule is a small-molecular compound, a polypeptide, an oligopeptide, a protein or a nucleic acid.

### Claim 37

A pharmaceutical composition for preventing and/or treating a brain disease comprising:
a peptide capable of permeating blood-brain barrier comprising at least one of the following amino acid sequence:
(i) a sequence consisting of SLSHSPQ (SEQ ID NO: 1), or
(ii) an amino acid sequence shown in SEQ ID NO: 1, in which P is substituted with an amino acid selected from the group consisting of A, I, L, V, M, F, W, Y, S, T, N, Q, H;
a drug to be delivered into the brain; and
a pharmacologically acceptable additive.

### Claim 38 (depends on 37)

The pharmaceutical composition according to claim 37, wherein the peptide is a cyclic peptide.

### Claim 39 (depends on 37)

The pharmaceutical composition according to claim 37, wherein the peptide is a peptide selected from the group consisting of the following (a) to (g):
(a) a peptide consisting of an amino acid sequence: SLSHSPQ (SEQ ID NO: 1),
(b) a peptide having 1 to 5 amino acid(s) at the C-terminal and/or the N-terminal of the amino acid sequence of SLSHSPQ (SEQ ID NO: 1) respectively,
(c) a peptide consisting of an amino acid sequence: CSLSHSPQC (SEQ ID NO: 2) in which cysteine residues in the sequence are disulfide-bonded,
(d) a peptide having 1 to 10 amino acid(s) at the C-terminal and/or the N-terminal of the amino acid sequence of CSLSHSPQC (SEQ ID NO: 2) respectively, in which cysteine residues in the sequence are disulfide-bonded,
(e) a peptide represented by an amino acid sequence of the following formula (1):
wherein, AAa and AAd each independently represent 1 to 10 amino acid(s), and AAb and AAc each independently represent 1 to 5 amino acids,
(f) a peptide having 1 to 15 amino acid(s) at the C-terminal and N-terminal of the amino acid sequence of SLSHSPQ (SEQ ID NO: 1) respectively, in which amino acids located on each side of the sequence are crosslinked together, and
(g) the peptide as described in any one of (a) to (f) above, in which P in the amino acid sequence SLSHSPQ is substituted with an amino acid selected from the group consisting of A, I, L, V, M, F, W, Y, S, T, N, Q, H and G.

### Claim 40 (depends on 37)

The pharmaceutical composition according to claim 37, wherein the drug is a molecule that exhibits a pharmacological action in the brain or an intracerebral imaging molecule.

### Claim 41 (depends on 37)

The pharmaceutical composition according to claim 37, wherein the molecule that exhibits a pharmacological action in the brain is a small-molecular compound, a polypeptide, an oligopeptide, a protein or a nucleic acid.

### Claim 42 (depends on 37)

The pharmaceutical composition according to claim 37, further comprising a substance selected from the group consisting of transferrin, fibrinogen, and a peptide containing RGD sequence.

### Claim 43 (depends on 37)

The pharmaceutical composition according to claim 37, further comprising a carrier molecule for drug delivery selected from the group consisting of liposomes, nanocarriers, exosomes, phages, polyrotaxanes, cyclodextrins, microcapsules and micelles.

### Claim 44

A method for preventing and/or treating a brain disease, comprising administering a prophylactically and/or therapeutically effective amount of the pharmaceutical composition to a subject in need of prevention and/or treatment of the brain disease, the pharmaceutical composition for preventing and/or treating a brain disease comprising:
a peptide capable of permeating blood-brain barrier comprising at least one of the following amino acid sequence:
(i) a sequence consisting of SLSHSPQ (SEQ ID NO: 1), or
(ii) an amino acid sequence shown in SEQ ID NO: 1, in which P is substituted with an amino acid selected from the group consisting of A, I, L, V, M, F, W, Y, S, T, N, Q, H;
a drug to be delivered into the brain; and
a pharmacologically acceptable additive.
